Fractional dosing of pneumococcal conjugate vaccine noninferior to full dosing schedule
1. In this randomized non-inferiority trial, 40% of a full dose of the 13-valent pneumococcal conjugate vaccine (PCV13) was noninferior ...
Tag: pulmonology
Reduced pneumococcal vaccine schedules non-inferior to WHO recommendations
1. In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a single primary ...
Amivantumab plus lazertinib improves survival in EGFR-mutated advanced NSCLC
1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung ...
Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer
1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo ...
Ziresovir reduces the severity of respiratory syncytial virus in hospitalized infants
1. Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and symptoms ...
Tirzepatide reduces obstructive sleep apnea symptoms and associated risks
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was found ...
Oxygen therapy for 15 versus 24 hours per day does not change hypoxemia-related mortality
1. In this randomized controlled trial, among patients with severe hypoxemia, long-term oxygen therapy used for 24 hours per day ...
Wearing surgical masks in public spaces reduces risks of respiratory symptoms
1. Wearing surgical face masks was superior to not wearing surgical face masks in reducing the risk of respiratory symptoms ...
Pantoprazole prophylaxis for individuals on mechanical ventilation with stress ulcers
1. In this randomized controlled trial studying critically ill adults, pantoprazole use was associated with a lower risk of clinically ...
Dupilumab reduces exacerbations in COPD with type 2 inflammation
1. In this randomized controlled trial, patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received dupilumab ...
